摘要 |
Disclosed is the use of bevacizumab and an anti-neoplastic composition, in the manufacture of a medicament for the treatment of cancer in a human patient, wherein the anti-neoplastic composition comprises at least one chemotherapeutic agent, and wherein the human patient is to be assessed for gastrointestinal perforation. Also disclosed is the use of bevacizumab in the manufacture of a medicament for treating a human patient susceptible to or diagnosed with colorectal cancer, wherein the human patient is to be assessed for gastrointestinal perforation. |